Overexpression of peroxiredoxin 2 inhibits TGF-β1-induced epithelial-mesenchymal transition and cell migration in colorectal cancer

Feng,Jihong; Fu,Zhongxue; Guo,Jinbao; Lu,Weidong; Wen,Kunming; Chen,Wangsheng; Wang,Hao; Wei,Jilai; Zhang,Shouru

doi:10.3892/mmr.2014.2316

Overexpression of peroxiredoxin 2 inhibits TGF-β1-induced epithelial-mesenchymal transition and cell migration in colorectal cancer

Authors:
- Jihong Feng
- Zhongxue Fu
- Jinbao Guo
- Weidong Lu
- Kunming Wen
- Wangsheng Chen
- Hao Wang
- Jilai Wei
- Shouru Zhang
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, The Affiliated Hospital, Zunyi Medical College, Zunyi, Guizhou 563003, P.R. China, The Affiliated Hospital, Luzhou Medical College, Luzhou, Sichuan 266003, P.R. China
Published online on: June 10, 2014 https://doi.org/10.3892/mmr.2014.2316
Pages: 867-873

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although human peroxiredoxin 2 (PRDX2) has been implicated in tumor progression (e.g., invasion and metastasis), little is known regarding its role in the epithelial‑mesenchymal transition (EMT) process during tumorigenesis. The present study offers the first evidence, to the best of our knowledge, that the antioxidant enzyme PRDX2 has an important role in regulating the EMT process. It was demonstrated that overexpression of PRDX2 leads to changes in cell morphology in vitro and potent inhibition of the transforming growth factor (TGF)‑β1‑induced EMT and cell migration of colorectal cancer (CRC) cells. Furthermore, PRDX2 regulates the expression of EMT markers, EMT‑related transcription factors and metastasis‑related factors in CRC cells. These results provide new insight into the role of PRDX2 in regulating EMT, cell migration and metastasis of CRC cells. It was concluded that the upregulation of PRDX2 may be correlated with EMT and contributes to the pathogenesis of CRC by inhibiting EMT, cell migration and metastasis. Taken together, these ﬁndings suggest that PRDX2 may be a key regulator of invasion and metastasis by inhibiting EMT of CRC cells, and also identifies a therapeutic strategy to effectively decrease the lethality of highly malignant types of CRC.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
2	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Developmental Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
3	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
4	Massagué J: TGFbeta in Cancer. Cell. 134:215–230. 2008.
5	Stefan Grünert MJHB: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol. 4:657–665. 2003.PubMed/NCBI
6	Voulgari A and Pintzas A: Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta. 1796:75–90. 2009.PubMed/NCBI
7	Zhao XL, Sun T, Che N, et al: Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1. J Cell Mol Med. 15:691–700. 2011. View Article : Google Scholar
8	Cho KH, Jeong KJ, Shin SC, Kang J, Park CG and Lee HY: STAT3 mediates TGF-beta1-induced TWIST1 expression and prostate cancer invasion. Cancer Lett. 336:167–173. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kalluri RWR: The basics of epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428. 2009. View Article : Google Scholar : PubMed/NCBI
10	Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol. 11:S44–S51. 2001.PubMed/NCBI
11	Sánchez-Tilló E, Liu Y, de Barrios O, et al: EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cellular and molecular life sciences. Cell Mol Life Sci. 69:3429–3456. 2012.PubMed/NCBI
12	Wood ZASE, Schröder E, Robin Harris J and Poole LB: Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 28:32–40. 2003. View Article : Google Scholar
13	Kang DH, Lee DJ, Lee KW, et al: Peroxiredoxin II is an essential antioxidant enzyme that prevents the oxidative inactivation of VEGF receptor-2 in vascular endothelial cells. Mol Cell. 44:545–558. 2011. View Article : Google Scholar : PubMed/NCBI
14	Ishii T, Warabi E and Yanagawa T: Novel roles of peroxiredoxins in inflammation, cancer and innate immunity. J Clin Biochem Nutr. 50:91–105. 2012.PubMed/NCBI
15	Rhee SG, Chae HZ and Kim K: Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 38:1543–1552. 2005. View Article : Google Scholar : PubMed/NCBI
16	Han YH, Kim HS, Kim JM, Kim SK, Yu DY and Moon EY: Inhibitory role of peroxiredoxin II (Prx II) on cellular senescence. FEBS Letters. 579:4897–4902. 2005. View Article : Google Scholar : PubMed/NCBI
17	Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J and Kang SW: Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. J Biol Chem. 286:8394–8404. 2011. View Article : Google Scholar : PubMed/NCBI
18	Choi MH, Lee IK, Kim GW, et al: Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature. 435:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
19	Agrawal-Singh S, Isken F, Agelopoulos K, et al: Genome-wide analysis of histone H3 acetylation patterns in AML identifies PRDX2 as an epigenetically silenced tumor suppressor gene. Blood. 119:2346–2357. 2012. View Article : Google Scholar : PubMed/NCBI
20	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
21	Wang Y and Shang Y: Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res. 319:160–169. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ko H, So Y, Jeon H, et al: TGF-beta1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett. 335:205–213. 2013. View Article : Google Scholar : PubMed/NCBI
23	Jarvis RM, Hughes SM and Ledgerwood EC: Peroxiredoxin 1 functions as a signal peroxidase to receive, transduce, and transmit peroxide signals in mammalian cells. Free Radic Biol Med. 53:1522–1530. 2012. View Article : Google Scholar : PubMed/NCBI
24	Manandhar G, Miranda-Vizuete A, Pedrajas JR, et al: Peroxiredoxin 2 and peroxidase enzymatic activity of mammalian spermatozoa. Biol Reprod. 80:1168–1177. 2009. View Article : Google Scholar : PubMed/NCBI
25	Neumann CA, Cao J and Manevich Y: Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 8:4072–4078. 2009. View Article : Google Scholar : PubMed/NCBI
26	Ha B, Kim EK, Kim JH, et al: Human peroxiredoxin 1 modulates TGF-β1-induced epithelial-mesenchymal transition through its peroxidase activity. Biochem Biophys Res Commun. 421:33–37. 2012.PubMed/NCBI
27	Chen X, Halberg RB, Burch RP and Dove WF: Intestinal adenomagenesis involves core molecular signatures of the epithelial-mesenchymal transition. J Mol Histol. 39:283–294. 2008. View Article : Google Scholar : PubMed/NCBI
28	Lee DJ, Kang DH, Choi M, et al: Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/beta-Catenin complexes in adherens junctions. Cancer Res. 73:4744–4757. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lu W, Fu Z, Wang H, Feng J, Wei J and Guo J: Peroxiredoxin 2 is upregulated in colorectal cancer and contributes to colorectal cancer cells’ survival by protecting cells from oxidative stress. Mol Cell Biochem. 387:261–270. 2014.PubMed/NCBI
30	Lu W, Fu Z, Wang H, Feng J, Wei J and Guo J: Peroxiredoxin 2 knockdown by RNA interference inhibits the growth of colorectal cancer cells by downregulating Wnt/β-catenin signaling. Cancer Lett. 343:190–199. 2014.PubMed/NCBI
31	Johnson RM, Ho YS, Yu DY, et al: The effects of disruption of genes for peroxiredoxin-2, glutathione peroxidase-1, and catalase on erythrocyte oxidative metabolism. Free Radic Biol Med. 48:519–525. 2010. View Article : Google Scholar : PubMed/NCBI
32	Shin SY, Kim CG, Jho EH, et al: Hydrogen peroxide negatively modulates Wnt signaling through downregulation of beta-catenin. Cancer Lett. 212:225–231. 2004. View Article : Google Scholar : PubMed/NCBI
33	Onder TT, Gupta PB, Mani SA, et al: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
34	Zhu QC, Gao RY, Wu W and Qin HL: Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev. 14:2689–2698. 2013. View Article : Google Scholar : PubMed/NCBI